Volume : 11, Issue : 07, July – 2024
Title:
TO DESIGN AND PHARMACOLOGICAL STUDY OF POLYHERBAL COMBINATION FOR THE TREATMENT OF GLOMERULONEPHRITIS
Authors :
Mr. Dipam Nilkanth Mahale, Dr. Aarti Dubey.
Abstract :
Glomerulonephritis is a kind of kidney disease. It involves damage to the glomeruli, tiny filters inside your kidneys. It’s caused by a variety of things, from infections to problems with the immune system. Sometimes glomerulonephritis is mild and soon goes away. Other times it hangs around and leads to kidney failure and other complications. Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually affecting both kidneys). Many of the diseases are characterized by inflammation either of the glomeruli or of the small blood vessels in the kidneys, hence the name, [1] but not all diseases necessarily have an inflammatory component.As it is not strictly a single disease, its presentation depends on the specific disease entity: it may present with isolated hematuria and/or proteinuria (blood or protein in the urine); or as a nephrotic syndrome, a nephritic syndrome, acute kidney injury, or chronic kidney disease. They are categorized into several different pathological patterns, which are broadly grouped into non-proliferative or proliferative types. Diagnosing the pattern of GN is important because the outcome and treatment differ in different types. Primary causes are intrinsic to the kidney. Secondary causes are associated with certain infections (bacterial, viral or parasitic pathogens), drugs, systemic disorders (SLE, vasculitis), or diabetes.
Keywords: Angelica officinalis Linn, Diuretic, Polyherbal, Glomerulonephritis.
Cite This Article:
Please cite this article in press Dipam Nilkanth Mahale et al., To Design And Pharmacological Study Of Polyherbal Combination For The Treatment Of Glomerulonephritis.,, Indo Am. J. P. Sci, 2024; 11 (07).
Number of Downloads : 10
References:
1. Abboud H and Henrich WL. Clinical practice. Stage IV chronic kidney disease. New. Engl. J. Med., 2010; 362:56–65.
2. Alelign T, Petros B. Kidney stone disease: An update on current concepts. Adv Urol 2018; 2018:3068365.
3. Anand R, Patnaik G, Srivastava S, Kulshreshtha D, Dhawan B. Evaluation of antiurolithiatic activity of Tribulus terrestris. Pharm Biol 2008; 32:217-24.
4. Barratt J. Interpretation and management of abnormal dipstick urinalysis. Med., 2011; 39:312–16.
5. Biglarkhani M, Zargar M, Hashem-Dabaghian F, Behbahani F, Behbahani A, Meyari A, et al. Common antiurolithiatic medicinal plants in Persian medicine: A review. Indo Am J P Sci 2017; 4:4838-4846.
6. Brosnahan G and Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. South. Med. Jour., 2010; 103:140–46.
7. Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: Alternative or complementary? Planta Med 2009; 75:1095-103.
8. Camkurt MA, Fındıklı E, Bakacak M, Tolun FI, Karaaslan MF. Evaluation of malondialdehyde, superoxide dismutase and catalase activity in fetal cord blood of depressed mothers. Clin Psychopharmacol Neurosci 2017; 15:35-9.
9. Chou CY, Kuo HL, Wang SM. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol. Dial. Transplant. 2010; 25:1225–30.
10. Cyril DG, Landry KS, François KYK, Abou B, Felix YH, Timothee OA. Evaluation of nephroprotective activity of aqueous and hydroethanolic extracts of Trema guineensis leaves (Ulmaceae) against gentamicin-induced nephrotoxicity in rats. Int. J. Bioch. Res. Rev., 2016; 15(2):1–10.
11. Davenport A, Anker SD, Mebazaa A. ADQI 7-The clinical management of the Cardio-Renal syndromes: Work group statements from the 7th ADQI consensus conference. Nephrol. Dial. Transplant. 2010; 25:2077–89.
12. De Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol., 2009; 20:2075–84.
13. Dipak P. Evaluation of the effect of Bryophyllum pinnatum Lam. and Boerhavia diffusa Linn. In experimentally induced renal stone in rats; 2017.
14. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ. Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis. Pediat. Nephrol., 2011;26:165–80.
15. Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol. Dia. Trans., 2012; 27(12):4288–94.
16. Foster MH. Novel targets for immunotherapy in glomerulonephritis. Biolo., 2008;2:531–45.
17. Gaur PK, Shanmugam SK. Box-behnken design-directed optimization of wickerhamomyces anomalus-mediated biotransformation process to enhance the flavonoid profile of polyherbal extract. J Pharm Innov 2020; 16, 481-492.
18. GBD 2015 disease and injury incidence and prevalence, collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016; 388(10053):1545–602.
19. Gordon E and Lash J. A timely change in CKD delivery: Promoting patient education. Am. J. Kid. Dis., 2011:375–77.
20. Goyal PK, Verma SK, Sharma AK. Evaluation of antiurolithiatic effects of Parmelia perlata against calcium oxalate calculi in hyperoxaluric rats. J App Pharm Sci 2018; 8:129-35.
21. Hodgkinson A, Williams A. An improved colorimetric procedure for urine and kidney homogenate oxalate. Clin Chim Acta 1972; 36:127-32.
22. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H, Tipiloura BT. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kid. Int., 2012; 81(10):1026–32.
23. Hussain AA, Mohammed AA, Ibrahim HH, Abbas AH. Study the biological activities of Tribulus terrestris extracts. World Acad Sci Eng Technol 2009; 33:510-2.
24. Ilyas M, Tolaymat A. Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study. Pediatr. Nephrol., 2008;23:1101–06.
25. Jarald EE, Kushwah P, Edwin S, Asghar S, Patni SA. Effect of unex on ethylene glycol-induced urolithiasis in rats. Indian J Pharmacol 2011; 43:466-8.
26. Jungraithmayr TC, Hofer K, Cochat P. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J. Am. Soc. Nephrol., 2011; 22:579–85.
27. Kamala A, Middha SK, Gopinath C, Sindhura HS, Karigar CS. In vitro antioxidant potentials of Cyperus rotundus L. rhizome extracts and their phytochemical analysis. Pharmacogn Mag 2018; 14:261-7.
28. Karadi RV, Gadge NB, Alagawadi KR, Savadi RV. Effect of Moringa oleifera Lam. root-wood on ethylene glycol induced urolithiasis in rats. J Ethnopharmacol 2006; 105:306-11.
29. Kawasaki Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment. Pediatr. Int., 2011; 53:795–06.
30. Kumar A. Drug Immunosuppression–Kidney Transplantation. Transplant. 2006; 81(9):1075.
31. Lash JP, Go AS, Appel LJ. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin. J. Am. Soc. Nephrol., 2009; 4:1302–11.
32. López-Novoa JM, Rodríguez-Peña AB, Alberto Ortiz, Carlos MS, López- Hernández JF. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications. J. Transla. Med., 2011; 9:13–18.
33. Masuda Y, Shimizu A, Kataoka M, Arai T, Ishikawa A, Du X. Inhibition of capillary repair in proliferative glomerulonephritis results in persistent glomerular inflammation with glomerular sclerosis. Lab. Invest., 2011; 90:1468–81.
34. Matsushita K, Van DV, Astor BC. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010; 375:2073–81.